27 Sep 2016 - 7:54pm

Call us: +44 (0) 207 754 0050

Press Releases

National Philanthropic Trust UK Supports London Lord Mayor’s Giving Day and #GivingTuesday Campaigns

[PRESSWIRE]  LONDON, United Kingdom - 27 September, 2016 -– National Philanthropic Trust UK (NPT-UK) announced today it supports the Lord Mayor’s Giving Day (27 September 2016) and the international campaign “GivingTuesday” (29 November 2016). NPT-UK is an independent UK registered charity dedicated to providing philanthropic expertise to donors, financial institutions, foundations and charities through donor advised funds (DAFs; a type of charitable savings account).

Selwood Asset Management Selects Quantifi’s Single Integrated Portfolio Management System

[PRESSWIRE] London and New York - 27 September, 2016 -- Quantifi, a specialist provider of risk, analytics and trading solutions, today announced that Selwood Asset Management, a newly authorised alternative investment manager, has confirmed the selection of Quantifi as its single Portfolio Management System (PMS).

YIT’s Renewed Strategy: Urban Development as the Engine of Growth

[PRESSWIRE] HELSINKI - 26 September, 2016 -- Regulatory News: YIT’s (HEX:YTY1V) Board of Directors has confirmed YIT’s renewed strategy for the next three-year period. The engine for growth and profitability is urban development involving partners. The company wants to differentiate itself by caring for customers, visionary urban development, passionate execution and inspiring leadership.

Cavion to Present Clinical Trial Preliminary Results at ASTRO

[PRESSWIRE] CHARLOTTESVILLE, Va. - 26 September, 2016 -- Cavion LLC, a pharmaceutical company developing T-type calcium channel (Cav3) inhibitors for the treatment of oncologic and neurologic diseases, announced today that Ranjit Bindra, MD, PhD and Nataniel Lester-Coll, MD will present preliminary results from an ongoing Yale University Cancer Center and Cavion-sponsored Phase 1 clinical trial at the Annual Meeting of the American Society for Therapeutic Radiation and Oncology (ASTRO) being held in Boston, Massachusetts, September 25-28.

AOR’s NEW RED YEAST RICE FORMULA RYR ANKASCIN -568-R™ OFFERS THE CARDIOVASCULAR HEALTH BENEFITS OF STATINS BUT WITHOUT THE SIDE EFFECTS

[PRESSWIRE] Calgary, Alberta, Canada - September 20, 2016 -- Developed by AOR, RYR Ankascin -568-R™ is the Only Patented, Clinically Studied, Regulatory Compliant, and Commercially Available Red Yeast Rice Extract Free of Monacolin K.

Pages

Subscribe to Press Releases